Mar 6, 2026 06:15PM
Mar 6, 2026 06:15PM
Jan 27, 2026 08:00AM
Jan 27, 2026 08:00AM
Jan 21, 2026 07:01AM
Jan 21, 2026 07:00AM
Jan 22, 2025 08:00AM Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Ade
Jan 21, 2025 08:14AM
May 9, 2024 04:05PM
Feb 29, 2024 04:05PM
Dec 12, 2023 08:00AM
Nov 2, 2023 04:05PM
Sep 6, 2023 08:00AM
Sep 6, 2023 08:00AM Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
Aug 14, 2023 04:05PM
Aug 14, 2023 04:05PM
May 24, 2023 08:00AM
May 9, 2023 04:05PM
May 9, 2023 04:05PM
Apr 20, 2023 08:30AM
Apr 20, 2023 08:30AM Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
Apr 18, 2023 08:30AM
Apr 18, 2023 08:30AM
Mar 30, 2023 04:05PM
Mar 30, 2023 04:05PM
Nov 10, 2022 04:05PM
Nov 10, 2022 04:05PM
Sep 29, 2022 08:00AM Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award
Sep 29, 2022 08:00AM
Sep 15, 2022 09:15AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All